Member Letter – January 2025
Dear Knopp Member: I am pleased to provide this update about Knopp and its interests in Areteia Therapeutics and...
2024 – Year End Financial Statements
[pdf-embedder...
Member Letter – October 2024
Re: Knopp Biosciences Distribution and Taxable Income Dear Knopp Member: Good news! The distribution checks went out...
2024 — Q3 Financial Statements
...
2024 — Q2 Financial Statements
[pdf-embedder...
Member Letter – May 2024
Dear Knopp Member: I am pleased to report that Knopp has restructured the contingent consideration under its 2022...
2024 — Q1 Financial Statements
...
Member Letter — December 2023
Dear Knopp Member: I am pleased to provide this update on recent activities at Knopp Biosciences as well as reports...
2023 – Year End Financial Statements
...
2023 — Q3 Financial Statements
...
Third Amended and Restated Operating Agreement
[pdf-embedder...
Amendment to Third Amended and Restated Operating Agreement
[pdf-embedder...
Second Amendment to Third Amended and Restated Operating Agreement
[pdf-embedder...
Series A-B Registration Rights Agreement
[pdf-embedder...
Amendment to Series A-B Registration Rights Agreement
[pdf-embedder...
Senior Class 1 Registration Rights Agreement
[pdf-embedder...
Investors’ Rights Agreement for Class C Units
[pdf-embedder...
2023 — Q2 Financial Statements
...
2023 — Q1 Financial Statements
...
2022 Financial Statements
[pdf-embedder...